Interleukin-1 antagonist Anakinra in amyotrophic lateral sclerosis - A pilot study

PLoS ONE

Volumn 10, Issue 10, 2015, Pages

  Maier, André ^a   Deigendesch, Nikolaus ^b   Müller, Kathrin ^c   Weishaupt, Jochen H ^c   Krannich, Alexander ^a   Röhle, Robert ^a   Meissner, Felix ^b   Molawi, Kaaweh ^b   Münch, Christoph ^a   Holm, Teresa ^a   Meyer, Robert ^a   Meyer, Thomas ^a   Zychlinsky, Arturo ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b MAX PLANCK INSTITUTE FOR INFECTION BIOLOGY   (Germany)

^c UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; FIBRINOGEN; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 6; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR ALPHA; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BACKACHE; BLEEDING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FEMALE; GASTRITIS; HEADACHE; HUMAN; INJECTION SITE REACTION; MALE; MIDDLE AGED; NEUROLOGIC DISEASE ASSESSMENT; OPEN STUDY; PAIN; PILOT STUDY; RESPIRATORY TRACT INFECTION; REVISED AMYOTROPIC LATERAL SCLEROSIS FUNCTIONAL RATING SCALE; SHOULDER PAIN; SIDE EFFECT; SWELLING; ANTAGONISTS AND INHIBITORS; DISEASE COURSE; DRUG EFFECTS; METABOLISM; MOTOR NEURON DISEASE; MUSCULOSKELETAL FUNCTION;

AGED; AMYOTROPHIC LATERAL SCLEROSIS; DISEASE PROGRESSION; FEMALE; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; MALE; MIDDLE AGED; MOTOR NEURON DISEASE; MUSCULOSKELETAL PHYSIOLOGICAL PHENOMENA; PILOT PROJECTS;

EID: 84948664501     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0139684     Document Type: Article

References (42)

1. Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O, et al. Amyotrophic lateral sclerosis. Lancet. 2011; 377(9769):942-55. Epub 2011/02/08. doi: 10.1016/S0140-6736(10)61156-7 PMID: 21296405.
2. Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. 2012; 3:CD001447. Epub 2012/03/16. doi: 10.1002/14651858.CD001447.pub3 PMID: 22419278.
3. Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med. 1994; 330(9):585-91. Epub 1994/03/03. doi: 10.1056/NEJM199403033300901 PMID: 8302340.
4. Anneser JM, Chahli C, Ince PG, Borasio GD, Shaw PJ. Glial proliferation and metabotropic glutamate receptor expression in amyotrophic lateral sclerosis. J Neuropathol Exp Neurol. 2004; 63(8):831-40. Epub 2004/08/28. PMID: 15330338.
5. McGeer PL, McGeer EG. Inflammatory processes in amyotrophic lateral sclerosis. Muscle Nerve. 2002; 26(4):459-70. Epub 2002/10/04. doi: 10.1002/mus.10191 PMID: 12362410.
6. Philips T, Robberecht W. Neuroinflammation in amyotrophic lateral sclerosis: role of glial activation in motor neuron disease. Lancet Neurol. 2011; 10(3):253-63. Epub 2011/02/26. doi: 10.1016/S1474-4422(11)70015-1 PMID: 21349440.
7. Turner MR, Cagnin A, Turkheimer FE, Miller CC, Shaw CE, Brooks DJ, et al. Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C](R)-PK11195 positron emission tomography study. Neurobiol Dis. 2004; 15(3):601-9. Epub 2004/04/02. doi: 10.1016/j.nbd.2003.12. 012 PMID: 15056468.
8. Mitchell RM, Freeman WM, Randazzo WT, Stephens HE, Beard JL, Simmons Z, et al. A CSF biomarker panel for identification of patients with amyotrophic lateral sclerosis. Neurology. 2009; 72 (1):14-9. Epub 2008/11/07. doi: 10.1212/01.wnl.0000333251.36681.a5 PMID: 18987350.
9. Martinon F, Mayor A, Tschopp J. The inflammasomes: guardians of the body. Annu Rev Immunol. 2009; 27:229-65. Epub 2009/03/24. doi: 10.1146/annurev.immunol.021908.132715 PMID: 19302040.
10. Ilzecka J, Stelmasiak Z, Dobosz B. Interleukin-1beta converting enzyme/Caspase-1 (ICE/Caspase-1) and soluble APO-1/Fas/CD 95 receptor in amyotrophic lateral sclerosis patients. Acta Neurol Scand. 2001; 103(4):255-8. Epub 2001/05/01. PMID: 11328198.
11. Li M, Ona VO, Guegan C, Chen M, Jackson-Lewis V, Andrews LJ, et al. Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model. Science. 2000; 288(5464):335-9. Epub 2000/04/15. PMID: 10764647.
12. Meissner F, Molawi K, Zychlinsky A. Mutant superoxide dismutase 1-induced IL-1beta accelerates ALS pathogenesis. Proc Natl Acad Sci U S A. 2010; 107(29):13046-50. Epub 2010/07/10. doi: 10.1073/pnas.1002396107 PMID: 20616033; PubMed Central PMCID: PMC2919927.
13. Dinarello CA, Simon A, van der Meer JW. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov. 2012; 11(8):633-52. Epub 2012/08/02. doi: 10.1038/nrd3800 PMID: 22850787; PubMed Central PMCID: PMC3644509.
14. Clark SR, McMahon CJ, Gueorguieva I, Rowland M, Scarth S, Georgiou R, et al. Interleukin-1 receptor antagonist penetrates human brain at experimentally therapeutic concentrations. J Cereb Blood Flow Metab. 2008; 28(2):387-94. Epub 2007/08/09. doi: 10.1038/sj.jcbfm.9600537 PMID: 17684519.
15. Galea J, Ogungbenro K, Hulme S, Greenhalgh A, Aarons L, Scarth S, et al. Intravenous anakinra can achieve experimentally effective concentrations in the central nervous system within a therapeutic time window: results of a dose-ranging study. J Cereb Blood Flow Metab. 2011; 31(2):439-47. Epub 2010/07/16. doi: 10.1038/jcbfm.2010.103 PMID: 20628399; PubMed Central PMCID: PMC3049499.
16. Emsley HC, Smith CJ, Georgiou RF, Vail A, Hopkins SJ, Rothwell NJ, et al. A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients. J Neurol Neurosurg Psychiatry. 2005; 76(10):1366-72. Epub 2005/09/20. doi: 10.1136/jnnp.2004.054882 PMID: 16170078; PubMed Central PMCID: PMC1739363.
17. Chiu IM, Phatnani H, Kuligowski M, Tapia JC, Carrasco MA, Zhang M, et al. Activation of innate and humoral immunity in the peripheral nervous system of ALS transgenic mice. Proc Natl Acad Sci U S A. 2009; 106(49):20960-5. Epub 2009/11/26. doi: 10.1073/pnas.0911405106 PMID: 19933335; PubMed Central PMCID: PMC2791631.
18. Kano O, Beers DR, Henkel JS, Appel SH. Peripheral nerve inflammation in ALS mice: cause or consequence. Neurology. 2012; 78(11):833-5. Epub 2012/03/02. doi: 10.1212/WNL.0b013e318249f776 PMID: 22377817; PubMed Central PMCID: PMC3304948.
19. Dobrowolny G, Aucello M, Molinaro M, Musaro A. Local expression of mIgf-1 modulates ubiquitin, caspase and CDK5 expression in skeletal muscle of an ALS mouse model. Neurol Res. 2008; 30(2):131-6. Epub 2008/04/10. doi: 10.1179/174313208X281235 PMID: 18397603.
20. Wong M, Martin LJ. Skeletal muscle-restricted expression of human SOD1 causes motor neuron degeneration in transgenic mice. Hum Mol Genet. 2010; 19(11):2284-302. Epub 2010/03/13. doi: 10. 1093/hmg/ddq106 PMID: 20223753; PubMed Central PMCID: PMC2865380.
21. Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial "Clinical limits of amyotrophic lateral sclerosis" workshop contributors. J Neurol Sci. 1994; 124 Suppl:96-107. Epub 1994/07/01. PMID: 7807156.
22. Hubers A, Marroquin N, Schmoll B, Vielhaber S, Just M, Mayer B, et al. Polymerase chain reaction and Southern blot-based analysis of the C9orf72 hexanucleotide repeat in different motor neuron diseases. Neurobiol Aging. 2014; 35(5):1214 e1-6. Epub 2014/01/01. doi: 10.1016/j.neurobiolaging.2013.11.034 PMID: 24378086.
23. Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci. 1999; 169(1-2):13-21. Epub 1999/12/14. PMID: 10540002.
24. Maier A, Holm T, Wicks P, Steinfurth L, Linke P, Munch C, et al. Online assessment of ALS functional rating scale compares well to in-clinic evaluation: a prospective trial. Amyotroph Lateral Scler. 2012; 13 (2):210-6. Epub 2012/02/02. doi: 10.3109/17482968.2011.633268 PMID: 22292842; PubMed Central PMCID: PMC3310482.
25. Anderson S. R. AA, Hauck W. W., Oakes D., Vandaele W., und Weisberg H. I. Statistical Methods for Comparative Studies: Techniques for Bias Reduction. John Wiley & Sons. 2009.
26. Bresnihan B. The safety and efficacy of interleukin-1 receptor antagonist in the treatment of rheumatoid arthritis. Semin Arthritis Rheum. 2001; 30(5 Suppl 2):17-20. Epub 2001/05/18. PMID: 11357167.
27. Turner MR, Hardiman O, Benatar M, Brooks BR, Chio A, de Carvalho M, et al. Controversies and priorities in amyotrophic lateral sclerosis. Lancet Neurol. 2013; 12(3):310-22. Epub 2013/02/19. doi: 10. 1016/S1474-4422(13)70036-X PMID: 23415570.
28. Keizman D, Rogowski O, Berliner S, Ish-Shalom M, Maimon N, Nefussy B, et al. Low-grade systemic inflammation in patients with amyotrophic lateral sclerosis. Acta Neurol Scand. 2009; 119(6):383-9. Epub 2008/11/04. doi: 10.1111/j.1600-0404.2008.01112.x PMID: 18976328.
29. Calabrese LH. Anakinra treatment of patients with rheumatoid arthritis. Ann Pharmacother. 2002; 36 (7-8):1204-9. Epub 2002/06/28. PMID: 12086555.
30. Gil J, Funalot B, Verschueren A, Danel-Brunaud V, Camu W, Vandenberghe N, et al. Causes of death amongst French patients with amyotrophic lateral sclerosis: a prospective study. Eur J Neurol. 2008; 15 (11):1245-51. Epub 2008/11/01. doi: 10.1111/j.1468-1331.2008.02307.x PMID: 18973614.
31. Corcia P, Pradat PF, Salachas F, Bruneteau G, Forestier N, Seilhean D, et al. Causes of death in a post-mortem series of ALS patients. Amyotroph Lateral Scler. 2008; 9(1):59-62. Epub 2007/10/10. doi: 10.1080/17482960701656940 PMID: 17924236.
32. den Broeder AA, de Jong E, Franssen MJ, Jeurissen ME, Flendrie M, van den Hoogen FH. Observational study on efficacy, safety, and drug survival of anakinra in rheumatoid arthritis patients in clinical practice. Ann Rheum Dis. 2006; 65(6):760-2. Epub 2005/11/05. doi: 10.1136/ard.2004.033662 PMID: 16269431; PubMed Central PMCID: PMC1798177.
33. Fleischmann RM, Schechtman J, Bennett R, Handel ML, Burmester GR, Tesser J, et al. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial. Arthritis Rheum. 2003; 48(4):927-34. Epub 2003/04/11. doi: 10.1002/art.10870 PMID: 12687534.
34. Drachman DB, Frank K, Dykes-Hoberg M, Teismann P, Almer G, Przedborski S, et al. Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS. Ann Neurol. 2002; 52(6):771-8. Epub 2002/11/26. doi: 10.1002/ana.10374 PMID: 12447931.
35. Cudkowicz ME, Shefner JM, Schoenfeld DA, Zhang H, Andreasson KI, Rothstein JD, et al. Trial of celecoxib in amyotrophic lateral sclerosis. Ann Neurol. 2006; 60(1):22-31. Epub 2006/06/28. doi: 10.1002/ana.20903 PMID: 16802291.
36. Gordon PH, Moore DH, Miller RG, Florence JM, Verheijde JL, Doorish C, et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol. 2007; 6 (12):1045-53. Epub 2007/11/06. doi: 10.1016/S1474-4422(07)70270-3 PMID: 17980667.
37. Gordon PH, Moore DH, Gelinas DF, Qualls C, Meister ME, Werner J, et al. Placebo-controlled phase I/II studies of minocycline in amyotrophic lateral sclerosis. Neurology. 2004; 62(10):1845-7. Epub 2004/05/26. PMID: 15159491.
38. ALSUntangled No. 19: Sodium chlorite. Amyotroph Lateral Scler Frontotemporal Degener. 2013; 14 (3):236-8. Epub 2013/02/21. doi: 10.3109/21678421.2013.769718 PMID: 23421652.
39. Beghi E, Chio A, Inghilleri M, Mazzini L, Micheli A, Mora G, et al. A randomized controlled trial of recombinant interferon beta-1a in ALS. Italian Amyotrophic Lateral Sclerosis Study Group. Neurology. 2000; 54(2):469-74. Epub 2000/02/11. PMID: 10668716.
40. Meyer T, Maier A, Borisow N, Dullinger JS, Splettstosser G, Ohlraun S, et al. Thalidomide causes sinus bradycardia in ALS. J Neurol. 2008; 255(4):587-91. Epub 2008/04/22. doi: 10.1007/s00415-008-0756-3 PMID: 18425621.
41. Stommel EW, Cohen JA, Fadul CE, Cogbill CH, Graber DJ, Kingman L, et al. Efficacy of thalidomide for the treatment of amyotrophic lateral sclerosis: a phase II open label clinical trial. Amyotroph Lateral Scler. 2009; 10(5-6):393-404. Epub 2009/11/20. doi: 10.3109/17482960802709416 PMID: 19922130; PubMed Central PMCID: PMC3820489.
42. Gordon PH, Cheng B, Salachas F, Pradat PF, Bruneteau G, Corcia P, et al. Progression in ALS is not linear but is curvilinear. J Neurol. 2010; 257(10):1713-7. Epub 2010/06/10. doi: 10.1007/s00415-010-5609-1 PMID: 20532545.